Literature DB >> 10945845

Nephroprotective effect of treatment with calcium channel blockers in spontaneously hypertensive rats.

M Sabbatini1, L Vitaioli, E Baldoni, F Amenta.   

Abstract

The influence of hypertension and of treatment with some dihydropyridine-type Ca(2+) channel blockers and with the nondihydropyridine-type vasodilator hydralazine on the morphology of kidney was investigated in 26-week-old spontaneously hypertensive rats (SHR) and in age-matched Wistar-Kyoto rats. Fourteen-week-old SHR were treated for 12 weeks with a nonhypotensive dose of lercanidipine or with equihypotensive doses of lercanidipine, manidipine, nicardipine, and hydralazine. In control SHR, systolic pressure values were significantly higher in comparison with Wistar-Kyoto rats. Treatment with the low dose of lercanidipine did not reduce systolic blood pressure in SHR, whereas the higher dose of lercanidipine or other compounds tested significantly decreased systolic pressure values. Glomerular hypertrophy accompanied by signs of glomerulosclerosis, increase of mesangial cells, and convoluted tubules degeneration were observed in control SHR. Hypotensive doses of Ca(2+) antagonists countered glomerular injury, the increase of mesangial cells, the reduction of capsular space, and tubular degeneration. Hydralazine, in spite of its hypotensive activity, displayed a slight nephroprotective action. The nonhypotensive dose of lercanidipine countered in part glomerular injury, narrowing of capsular space, and tubular degeneration, and decreased mesangial cell augmentation in SHR. These results suggest that treatment with dihydropyridine-type Ca(+2) antagonists counters hypertensive glomerular and tubular changes occurring in SHR. The demonstration of nephroprotection by the nonhypotensive dose of lercanidipine suggests that the renal effects of the compound may be in part unrelated to its hemodynamic activity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10945845

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

Review 1.  Fixed-dose combination lercanidipine/enalapril.

Authors:  Philip I Hair; Lesley J Scott; Caroline M Perry
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 2.  Manidipine: a review of its use in hypertension.

Authors:  S M Cheer; K McClellan
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 3.  Lercanidipine : a review of its efficacy in the management of hypertension.

Authors:  Lynne M Bang; Therese M Chapman; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 4.  Lercanidipine in hypertension.

Authors:  Claudio Borghi
Journal:  Vasc Health Risk Manag       Date:  2005

5.  Histopathological characteristics of renal changes in human renin-angiotensinogen double transgenic rats.

Authors:  Tomoaki Tochitani; Masaya Mori; Koichi Matsuda; Mami Kouchi; Yuta Fujii; Izumi Matsumoto
Journal:  J Toxicol Pathol       Date:  2015-12-12       Impact factor: 1.628

6.  Effect of Cyclooxygenase(COX)-1 and COX-2 inhibition on furosemide-induced renal responses and isoform immunolocalization in the healthy cat kidney.

Authors:  L Pelligand; N Suemanotham; J N King; W Seewald; H Syme; K Smith; P Lees; J Elliott
Journal:  BMC Vet Res       Date:  2015-12-03       Impact factor: 2.741

Review 7.  Lercanidipine in the Management of Hypertension: An Update.

Authors:  Guido Grassi; Nicolàs R Robles; Gino Seravalle; Francesco Fici
Journal:  J Pharmacol Pharmacother       Date:  2017 Oct-Dec

8.  Antioxidant Properties of Alpha-Lipoic (Thioctic) Acid Treatment on Renal and Heart Parenchyma in a Rat Model of Hypertension.

Authors:  Ilenia Martinelli; Daniele Tomassoni; Proshanta Roy; Lorenzo Di Cesare Mannelli; Francesco Amenta; Seyed Khosrow Tayebati
Journal:  Antioxidants (Basel)       Date:  2021-06-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.